These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12789608)

  • 1. Chronogesic (DURECT).
    Joshi GP
    IDrugs; 2003 Apr; 6(4):368-71. PubMed ID: 12789608
    [No Abstract]   [Full Text] [Related]  

  • 2. EN-3231. Endo Pharmaceuticals.
    Monck N
    Curr Opin Investig Drugs; 2002 Mar; 3(3):459-62. PubMed ID: 12054097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strong analgesics: working towards an optimal balance between efficacy and side effects.
    Varrassi G; Marinangeli F; Piroli A; Coaccioli S; Paladini A
    Eur J Pain; 2010 Apr; 14(4):340-2. PubMed ID: 20219399
    [No Abstract]   [Full Text] [Related]  

  • 4. A review of intrathecal fentanyl and sufentanil for the treatment of chronic pain.
    Waara-Wolleat KL; Hildebrand KR; Stewart GR
    Pain Med; 2006; 7(3):251-9. PubMed ID: 16712626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E-TRANS fentanyl. ALZA.
    Mystakidou K
    Curr Opin Investig Drugs; 2002 Mar; 3(3):463-9. PubMed ID: 12054098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [What is the dosage recommendation for sufentanil and fentanyl?].
    Janson W; Kopf A
    Anaesthesist; 1999 Mar; 48(3):188-9. PubMed ID: 10234402
    [No Abstract]   [Full Text] [Related]  

  • 7. Subarachnoid sufentanil for early postoperative pain management in orthopedic patients: more disadvantages than benefits?
    Gebhard RE; Fanelli G; Matuszczak M; Doehn M
    Anesthesiology; 2001 Dec; 95(6):1531-3. PubMed ID: 11780176
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral transmucosal fentanyl and sufentanil for incident pain.
    Gardner-Nix J
    J Pain Symptom Manage; 2001 Aug; 22(2):627-30. PubMed ID: 11503630
    [No Abstract]   [Full Text] [Related]  

  • 9. Pupillary response in patients receiving intrathecal sufentanil.
    Wang YC; Guo QL; Wang E; Zhong T; Huang CS; Peng J
    Chin Med J (Engl); 2007 Jul; 120(14):1274-6. PubMed ID: 17697584
    [No Abstract]   [Full Text] [Related]  

  • 10. Sufentanil in anaesthesiology and intensive therapy.
    Maciejewski D
    Anaesthesiol Intensive Ther; 2012; 44(1):35-41. PubMed ID: 23801512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic pain of osteoarthritis: considerations for selecting an extended-release opioid analgesic.
    Gibofsky A; Barkin RL
    Am J Ther; 2008; 15(3):241-55. PubMed ID: 18496262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: systematic review of long-acting oral opioids.
    Manchikanti L; Boswell MV; Atluri S
    J Pain Symptom Manage; 2004 Sep; 28(3):194-5; author reply 195. PubMed ID: 15336326
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical use of sufentanil].
    Toftegaard M; Pedersen PF; Hansen PA; Knudsen F
    Ugeskr Laeger; 1996 Jun; 158(24):3483-6. PubMed ID: 8650823
    [No Abstract]   [Full Text] [Related]  

  • 14. Pilot dose finding study of intranasal sufentanil for breakthrough and incident cancer-associated pain.
    Jackson K; Ashby M; Keech J
    J Pain Symptom Manage; 2002 Jun; 23(6):450-2. PubMed ID: 12067765
    [No Abstract]   [Full Text] [Related]  

  • 15. Extended-release opioids for the management of chronic non-malignant pain.
    Sloan P; Babul N
    Expert Opin Drug Deliv; 2006 Jul; 3(4):489-97. PubMed ID: 16822224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical considerations in analgesic therapy. II. Narcotic analgesics.
    Lipman AG; Brooks KJ
    PA J; 1976; 6(2):68-71. PubMed ID: 16247
    [No Abstract]   [Full Text] [Related]  

  • 17. Preliminary results of prolonged target controlled infusion of sufentanil adjusted to an effort pain score after cardiac surgery.
    Bastin R; Barvais L; Mélot C; Vincent JL; Berré J
    Acta Anaesthesiol Belg; 2005; 56(1):31-6. PubMed ID: 15822418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pooled Phase III safety analysis of sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain.
    Miner JR; Melson TI; Leiman D; Minkowitz HS; Chiang YK; DiDonato KP; Palmer PP
    Pain Manag; 2019 May; 9(3):259-271. PubMed ID: 30614379
    [No Abstract]   [Full Text] [Related]  

  • 19. Tramadol and strong opioid: synergistic or additive opioid effect?
    Di Lorenzo L
    Pain Pract; 2008; 8(3):214-5; author reply 215-6. PubMed ID: 18476900
    [No Abstract]   [Full Text] [Related]  

  • 20. Intranasal sufentanil for cancer-associated breakthrough pain.
    Good P; Jackson K; Brumley D; Ashby M
    Palliat Med; 2009 Jan; 23(1):54-8. PubMed ID: 19144765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.